Salute e Benessere

Zelluna ASA Reports Third Quarter 2025 Financial Results and Provides General…

Oslo, Norway, 3 November 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic “off-the-shelf” T-cell receptor-based natural killer (TCR-NK) therapies for the treatment of cancer, announces its third quarter 2025 results today.Webcast scheduled for 4 November 2025, at 09:00 (CET). Link to webcast here . Third Quarter 2025 Business UpdateHighlights Positive MHRA feedback and strengthened clinical strategy supporting UK clinical developmentIn October 2025...
Nasdaq GlobeNewswire
03/11/2025

ECG Cable & Lead Wire Market worth $3.76 billion by 2030 with 6.8% CAGR |…

Browse in-depth TOC on "ECG Cables and Lead Wires Market"280 - Tables64 - Figures300 - Pages Browse in-depth TOC on "ECG Cables and Lead Wires Market" 280 - Tables 64 - Figures 300 - Pages By ECG lead wire type,the ECG cable & lead wire market is segmented into ECG lead wire and ECG cable. The ECG lead wire market is divided into 12-lead ECG wires, 5-lead ECG wires, 3-lead ECG wires, 6-lead ECG wires, single-lead ECG wires, and other ECG lead wires. In 2024, 12-lead…
PR Newswire
03/11/2025

Personal Care Emulsifiers Market to Reach $2.8 Billion, Globally, by 2034 at…

Rising Male Grooming Trends Rising Male Grooming Trends The rising trend in male grooming is significantly contributing to the growth of the Personal Care Emulsifiers market. The personal care industry was largely female-centric, but recent years have seen a shift in consumer behavior, with men increasingly investing in grooming and skincare routines. This trend is particularly evident in urban areas where lifestyle changes, greater awareness of personal hygiene, and the influence of...
PR Newswire
03/11/2025

Latest Real-World Clinical Data Demonstrate a 19.6 mmHg Reduction in Blood…

19.6 mmHg BP Reduction in 6-Month Data from the GPS Registry The GPS Registry is a real world, all comers, prospective and retrospective registry being conducted in nine countries outside ofthe United States, designed to assess the long-term safety and effectiveness of the Paradise uRDN system when used according to its labeling. Presented by Dr.Karl Fengler, Heart Center,Leipzig, the results included the first prospective analysis of data from 212 patients...
PR Newswire
03/11/2025

Peli BioThermal Opens Expanded Allentown, PA Service Center to Support Growing…

"To us, this new facility represents more than just additional space—it reflects Peli BioThermal's continued growth, commitment to innovation, and unwavering focus on supporting our customers," said Sam Herbert, CEO of Peli BioThermal. "We are investing in the future of cold chain logistics to ensure we deliver the flexibility, reliability, and protection our customers need for their life-saving therapies." "To us, this new facility represents more than just additional…
PR Newswire
03/11/2025

Cellectis to Present a Development Update for eti-cel at ASH 2025

Preliminary data recently shared for eti-cel (UCART20x22) show an 86% ORR and a 57% CR rate (n=7), underscoring its potential to improve outcomes in r/r NHLPreclinical data demonstrated that combining eti-cel with low-dose IL-2 may deepen and extend anti-tumor activity in patients with r/r NHLEti-cel full Phase 1 dataset, including low-dose IL-2 combination cohorts, expected to be presented in 2026Correlation between alemtuzumab exposure and response with lasme-cel...
Nasdaq GlobeNewswire
03/11/2025

Genmab to Showcase Latest Blood Cancer Treatment Advancements at 2025 American…

Media ReleaseCOPENHAGEN, Denmark; November 3, 2025 More than 20 abstracts, including seven oral presentations, highlight advancements from the epcoritamab development program supporting the expanded clinical profile and potential of epcoritamab for a broader range of B-cell malignanciesNew data demonstrate potential of epcoritamab in first and second-line settings in follicular lymphoma (FL) and first-line in diffuse large B-cell lymphoma (DLBCL) Results from Phase 3 EPCORE...
Nasdaq GlobeNewswire
03/11/2025

Roche to present new data from its broad and innovative haematology portfolio at…

Findings further demonstrate the effectiveness of Roche’s approved medicines in advancing treatment standards for people with blood disordersData from innovative pipeline signals progress toward improved outcomes in haemophilia A, lymphoma, and multiple myeloma Basel, 3 November 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will showcase 46 abstracts, including 12 oral presentations, from its industry-leading haematology portfolio at the 67 thAmerican Society...
Nasdaq GlobeNewswire
03/11/2025

Evaxion expands R&D pipeline with new AI-designed precision cancer vaccine…

Evaxion introduces EVX-04, a novel vaccine candidate targeting multiple non-conventional ERV tumor antigens, developed withour AI-Immunology™ platformEVX-04 is a therapeutic cancer vaccine candidate designed for acute myeloid leukemiaNew data showing EVX-04 induces strong T-cell responses and cancer cell killing will be presented at an oral session at the American Society of Hematology (ASH) Annual Meeting and Exposition in Florida on December 6, 2025The concept behind EVX-04...
Nasdaq GlobeNewswire
03/11/2025

AIM ImmunoTech Announces European Patent Office Grants Patent Covering Ampligen®…

AIM ImmunoTech Inc.(NYSE American: AIM) (“AIM” or the “Company”) today announced that the European Patent Office has officially granted AIM’s European Patent No. 4,096,675, titled “Compositions for Treating LONG COVID,” covering compositions of matter of AIM’s proprietary dsRNAs including, for example, Ampligen ® (rintatolimod) for use in the treatment of Long COVID.“While AIM’s immediate and primary focus is to build upon the continued positive results from our late-stage pancreatic...
Nasdaq GlobeNewswire
03/11/2025

Lilly plans to build a new €2.6 billion facility to boost oral medicine…

The facility will incorporate advanced manufacturing technologies to meet the needs of Lilly's growing portfolio of oral solid medicines in cardiometabolic health, neuroscience, oncology and immunology. Innovative capabilities will include dock-to-dock automation and material flow, paperless manufacturing, process analytical technology and spray-dried dispersion, which allows oral medicines to be effectively absorbed. The facility will incorporate advanced manufacturing technologies to meet...
PR Newswire
03/11/2025

Ardena strengthens executive leadership with appointments of Chief Quality…

Dipesh Patel brings more than 25 years of experience in the pharmaceutical industry, having held senior leadership roles across CDMOs, virtual biotech companies, and large-scale manufacturing organizations. With an academic background in Chemistry, Biology, and Toxicology, he has built a strong track record in both Quality and Operations, overseeing a broad range of dosage forms and regulatory frameworks. His global experience provides deep insight into diverse regulatory requirements and...
Nasdaq GlobeNewswire
03/11/2025

Teva Kicks Off ‘The Other TD’ to Raise Awareness of Tardive Dyskinesia (TD)…

This football season, Teva is increasing education around tardive dyskinesia (TD) by launching ‘The Other TD’ campaignTD is a chronic movement disorder impacting one in four people who take certain prescription mental health medications. While TD can impact your daily life, it can be treated without interrupting your mental health treatment 1-4 Younger individuals, men, and racial and ethnic minority groups have lower rates of formal diagnoses despite the...
Nasdaq GlobeNewswire
03/11/2025

Biogen to Highlight Scientific Progress in Rare Kidney Disease at American…

Oral presentation to share first-of-its-kind longitudinal gene expression data in IgA nephropathy, unveiling novel insights into the mechanism of action of felzartamab and advancing the understanding of its disease modifying potentialExhibitor Spotlight to discuss role of CD38 cells across a range of immune-mediated kidney diseasesFelzartamab, an investigational anti-CD38 monoclonal antibody, is a potentially differentiated therapeutic candidate with promise for a broad range of...
Nasdaq GlobeNewswire
03/11/2025

uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease

uniQureN.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it received feedback from the U.S. Food and Drug Administration (FDA) during a recent pre-Biologics License Application (BLA) meeting regarding AMT-130, an investigational gene therapy for Huntington’s disease (HD). Though final meeting minutes have not yet been received, based on the discussions at the meeting, uniQure believes that...
Nasdaq GlobeNewswire
03/11/2025

BioNTech Announces Third Quarter 2025 Financial Results and Corporate Update

Continued clinical execution of oncology strategy with focus on two pan-tumor programs, including combination approaches to address the full continuum of cancer from early to late disease stagesDemonstrated encouraging anti-tumor activity and manageable safety profile of pumitamig (BNT327/BMS986545), a bispecific antibody candidate targeting PD-L1 1and VEGF-A, in first disclosed interim data from global Phase 2 trial in extensive-stage small cell lung cancer Plan to initiate...
Nasdaq GlobeNewswire
03/11/2025

TCT 2025 | Robot-Assisted PCI Enters a New Era: Results of the PANVIS STAR…

In traditional PCI procedures, vascular interventional physicians must wear heavy lead aprons and operate for extended periods under X-ray, facing multiple occupational risks such as an increased incidence of orthopedic and ophthalmic diseases. With the advancement of precision medicine and telemedicine, robot-assisted PCI has become a key pathway to address these challenges. However, most current interventional robots rely on joystick control, making it difficult to simulate physicians'…
PR Newswire
03/11/2025

Pulsenmore Receives FDA De Novo Marketing Authorization for Home-Use Prenatal…

The Pulsenmore ES integrates at-home ultrasound imaging into physician-led prenatal care. The Pulsenmore cradle connects to the patient's smartphone and guides her step-by-step via the Pulsenmore app. Captured video clips are securely transmitted to physicians for review and interpretation on a dedicated dashboard. Pulsenmore's U.S. clinical validation was achieved through a multi-center trial conducted at four leading academic and clinical institutions. The Pulsenmore ES integrates at-home...
PR Newswire
03/11/2025

Naturecan Welcomes FDA NMN Ruling, Unlocking New Global Opportunities

Naturecan, a global wellness brand committed to science-backed innovation, sees this as a pivotal moment for the future of nutrition. Naturecan, a global wellness brand committed to science-backed innovation, sees this as a pivotal moment for the future of nutrition. "The FDA's re-evaluation of NMN is a global milestone. It demonstrates growing recognition of NMN as a trusted supplement ingredient and opens the door for consumers in the U.S. to access it more easily again," said…
PR Newswire
03/11/2025

PureHealth Delivers Strong 9-Month Results with AED 20.1 Billion in Revenue and…

The transaction was funded through PureHealth's strong balance sheet, underscoring the Group's financial strength as it continues to scale and pursue strategic growth opportunities. Financial contributions from the acquisition are being recognised from 1 October 2025, reflecting the group's continued international expansion and operational scale. PureHealth now holds 52% of its assets outside UAE. The transaction was funded through PureHealth's strong balance sheet, underscoring the Group's...
PR Newswire
03/11/2025

Avance Clinical Showcases Early Phase Expertise and the Australian Advantage for…

Helping European Biotechs Accelerate Early Phase Success With Faster Timelines, Lower Costs, and Globally Accepted Data Avance Clinical, the largest premium full-service Australian headquartered CRO with more than 30 years of early phase expertise, is highlighting its Early Phase Center of Excellence for Biotechs and the well-established Australian Advantage to European biotechs ahead ofBIO-Europe in Vienna, November 3-5, 2025.European biotechs under increasing investor and...
Nasdaq GlobeNewswire
03/11/2025

AAVantgarde Closes $141 Million Series B Financing to Advance its Clinical…

LONDON and MILAN, Nov.03, 2025(GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage, biotechnology company pioneering therapies for inherited retinal diseases (IRDs), today announced the successful closing of a $141 million (€122 million) Series B financing round.The round was co-led by a new lead, Schroders Capital, as well as existing investors Atlas Venture and Forbion. Other new investors included Amgen Ventures, Athos Capital, CDP Venture Capital through its Large...
Nasdaq GlobeNewswire
03/11/2025

ArisGlobal Announces NavaX™ Agents Suite

Building on ArisGlobal's long-standing commitment to AI with purpose, NavaX Agents represent a new generation of autonomous, domain-trained digital agents designed to reason, act, and collaborate within the LifeSphere Unify platform. Each Agent is built to perform specialized, high-impact tasks—continuously learning from human input and organizational context to provide intelligence and insights like never before, while delivering even greater accuracy, efficiency, and compliance. Building on...
PR Newswire
03/11/2025

Sandstone Easydrip™ Plus with Hextra Tech™ Hexagonal Broad Hub Delivers…

What sets Easydrip™ Plus apart What sets Easydrip™ Plus apart Why it matters Pen-needle stability and comfort directly influence user confidence and adherence. A hub that resists tilt can minimize off-target delivery and help make frequent self-injections feel more manageable—outcomes Easydrip™ Plus is designed to support. Regulatory snapshot About Sandstone and SteriLance Sandstone Medical is the diabetes-care brand of SteriLance Medical, developing pen needles, safety...
PR Newswire
03/11/2025
Altri  Comunicati